Amplify Treatments, Testing and Adv ETF (GERM)
16.64
+0.29
(+1.78%)
USD |
NYSEARCA |
Apr 22, 16:00
16.70
+0.06
(+0.38%)
After-Hours: 20:00
Price Chart
Key Stats
Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
---|---|---|---|
0.68% | -0.09% | 9.159M | 1691.60 |
Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
1.54% | -- | -- | Upgrade |
Basic Info
Investment Strategy | |
The investment seeks investment results that generally correlate to the total return performance of the Prime Treatments, Testing and Advancements Index. Under normal circumstances, the fund invests at least 80% of its net assets in U.S.-listed equity securities or ADRs of Treatments, Testing and Advancements Companies. In general, the index seeks to be comprised of companies performing advancements in research, development, and commercialization of treatments or vaccines for infectious diseases, or engaged in the advancement of research, development, manufacturing, and provision of biological tests for patients. The fund is non-diversified. |
General | |
Security Type | Exchange-Traded Fund |
Equity Style | Small Cap/Blend |
Fixed Income Style | -- |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Category Name | Health |
Category Index | S&P 1500 Health Care TR |
Global Category Name | Healthcare Sector Equity |
YCharts Categorization | Healthcare Equity |
YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
Prospectus Objective | Specialty - Health |
Fund Owner Firm Name | Amplify ETFs |
Prospectus Benchmark Index | |
Prime Treatm, Testing and Adv TR USD | 100.0% |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Manager Tenure | |
Charles Ragauss | 3.79 yrs |
Qiao Duan | 3.79 yrs |
Performance Versus Category
As of April 22, 2024. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of April 22, 2024.
Basic Info
Investment Strategy | |
The investment seeks investment results that generally correlate to the total return performance of the Prime Treatments, Testing and Advancements Index. Under normal circumstances, the fund invests at least 80% of its net assets in U.S.-listed equity securities or ADRs of Treatments, Testing and Advancements Companies. In general, the index seeks to be comprised of companies performing advancements in research, development, and commercialization of treatments or vaccines for infectious diseases, or engaged in the advancement of research, development, manufacturing, and provision of biological tests for patients. The fund is non-diversified. |
General | |
Security Type | Exchange-Traded Fund |
Equity Style | Small Cap/Blend |
Fixed Income Style | -- |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Category Name | Health |
Category Index | S&P 1500 Health Care TR |
Global Category Name | Healthcare Sector Equity |
YCharts Categorization | Healthcare Equity |
YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
Prospectus Objective | Specialty - Health |
Fund Owner Firm Name | Amplify ETFs |
Prospectus Benchmark Index | |
Prime Treatm, Testing and Adv TR USD | 100.0% |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Manager Tenure | |
Charles Ragauss | 3.79 yrs |
Qiao Duan | 3.79 yrs |